Advertisement

Topics

Search Results for "Hydrocodone Bitartrate 7 5 Mg"

13:15 EDT 23rd June 2017 | BioPortfolio

Matching Channels

None

Matching News

Perrigo Announces FDA Final Apffproval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution

Lannett Receives Approval For Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg And 10 mg/300 mg

PHILADELPHIA, June 22, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug App...

Lupin launches Hydrocodone Bitartrate generic

Brian BerkIt is indicated for the relief of moderate to moderately severe pain. read more

Hydrocodone Bitartrate Industry Key Players and Market Analysis Says a New Research Report at DeepResearchReports.com

PUNE, India, May 31, 2017 /PRNewswire/ -- Global Hydrocodone Bitartrate Market 2017 Research Report initially provides a basic overview of the industry that covers definition, applications and man...

FDA approves Perrigo’s hydrocodone bitartrate and homatropine methylbromide

Brian BerkThe solutions are indicated for the symptomatic relief of cough in adults and children 6 years of age and older. read more

Generic pain drug launched by Lupin

The AA-rated generic version of Mikart's Hydrocodone Bitartrate and Acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and -More- 

FDA OKs generic cough syrup from Lupin

Lupin's abbreviated new drug application for hydrocodone bitartrate and homatropine methylbromide oral solution has been appr -More- 

Perrigo's cough solution gets FDA nod

The FDA has granted final approval to Perrigo's hydrocodone bitartrate and homatropine methylbromide oral solution to relieve -More- 

Matching PubMed Articles

Hydrocodone Bitartrate ER (Hysingla(®) ER): A Review in Chronic Pain.

Hydrocodone bitartrate extended-release (Hysingla(®) ER; referred to hereafter as hydrocodone ER) was the first single-entity hydrocodone formulation recognized by the US FDA as having abuse-deterren...

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

 A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER [HYD]) is available for the treatment of chronic pain in appropriate patients. This study e...

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain.

This study evaluated the safety and effectiveness of a once-daily, single-entity, extended-release hydrocodone bitartrate (HYD) among patients with chronic noncancer and non-neuropathic pain who requi...

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.

Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential effect can have significant detrimental ...

The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.

In 2012, hydrocodone combination products (HCPs) were the most prescribed medications in the United States. Under the Controlled Substance Act of 1970, hydrocodone alone was classified as a Schedule I...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement